These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31858818)

  • 1. Experience with eribulin in pretreated patients with advanced liposarcoma: a case series.
    Paioli A; Setola E; Palmerini E; Cesari M; Longhi A
    Future Oncol; 2020 Jan; 16(1s):25-32. PubMed ID: 31858818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient.
    Miano ST; Francini E; Petrioli R; Francini G
    Future Oncol; 2020 Jan; 16(1s):33-38. PubMed ID: 31975628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dedifferentiated liposarcoma: when eribulin can make the difference.
    Sbrana A; Paolieri F; Bloise F; Manacorda S; Nuzzo A; Sammarco E; Galli L; Falcone A
    Future Oncol; 2020 Jan; 16(1s):21-24. PubMed ID: 31872768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term eribulin treatment in patients with a single kidney and retroperitoneal liposarcoma.
    Tober N; Gentile M; Iodice G
    Future Oncol; 2020 Jan; 16(1s):5-8. PubMed ID: 31872769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma.
    Martorana F; Vigneri P; Manzella L; Tirrò E; Soto Parra HJ
    Future Oncol; 2020 Jan; 16(1s):9-13. PubMed ID: 31916463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
    Schöffski P; Chawla S; Maki RG; Italiano A; Gelderblom H; Choy E; Grignani G; Camargo V; Bauer S; Rha SY; Blay JY; Hohenberger P; D'Adamo D; Guo M; Chmielowski B; Le Cesne A; Demetri GD; Patel SR
    Lancet; 2016 Apr; 387(10028):1629-37. PubMed ID: 26874885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eribulin rapidly reduces the aggressiveness of second primary breast cancer: a case report.
    Falco I; Stragliotto S
    Future Oncol; 2017 Apr; 13(11s):51-54. PubMed ID: 28481187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment with eribulin in heavily pretreated women with metastatic breast cancer: a case series.
    Morritti M; Iodice G; Melaccio A; D'Onofrio L; Bergnolo P; Boglione A; Comandone A; Molinaro P; Garigliano D
    Future Oncol; 2017 Apr; 13(11s):25-33. PubMed ID: 28481183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eribulin long-term response and rechallenge: report of two clinical cases.
    Barbieri E; Rubino D; Hakim R; Fini A; Lenzi M; Zamagni C
    Future Oncol; 2017 Apr; 13(11s):35-43. PubMed ID: 28481188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to eribulin in a difficult-to-treat, heavily pretreated breast cancer patient: a case report.
    Leo L; Caputo F; Sarno AD; Garofano T; Andreozzi F; Massaro MG; Montesarchio V
    Future Oncol; 2015; 11(15 Suppl):27-30. PubMed ID: 26235262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.
    Park YH; Kim TY; Im YH; Lee KS; Park IH; Sohn J; Lee SH; Im SA; Kim JH; Kim SH; Lee SJ; Koh SJ; Lee KH; Choi YJ; Cho EK; Lee S; Kang SY; Seo JH; Kim SB; Jung KH
    Cancer Res Treat; 2017 Apr; 49(2):423-429. PubMed ID: 27488876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eribulin efficacy based on type of metastatic site: a real-life study in heavily pretreated metastatic breast cancer.
    Prestifilippo A; Grippaldi D; Blanco G; Memeo L; Puliafito I; Giuffrida D
    Future Oncol; 2017 Apr; 13(11s):5-10. PubMed ID: 28481186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to eribulin in a patient with metastatic uterine leiomyosarcoma: a case report.
    Aliberti S; Miano S; Tolomeo F; Merlini A; Aglietta M; Grignani G
    Future Oncol; 2020 Jan; 16(1s):15-19. PubMed ID: 31916842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eribulin as an effective monotherapy in a chemo-pretreated woman with metastatic breast cancer: a case report.
    Caputo R; Cianniello D; De Laurentiis M
    Future Oncol; 2017 Apr; 13(11s):45-50. PubMed ID: 28481184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience.
    Martella F; Bacci C; Giordano C; Montagnani F; Gelain E; Rabatti L; Fioretto L
    Future Oncol; 2015; 11(15 Suppl):31-6. PubMed ID: 26235263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.
    Rau KM; Ou-Yang F; Chao TC; Kuo YL; Cheng TF; Chao TY; Chen DR; Tzeng YD; Wang BW; Liu CY; Hu MH; Lu YC; Ou WJ; Kuo CH; Chuang CH; Kan JY; Chen FM; Hou MF
    Breast Cancer Res Treat; 2018 Aug; 170(3):583-591. PubMed ID: 29623575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Approval Summary: Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing Regimen.
    Osgood CL; Chuk MK; Theoret MR; Huang L; He K; Her L; Keegan P; Pazdur R
    Clin Cancer Res; 2017 Nov; 23(21):6384-6389. PubMed ID: 28242632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital.
    Poletti P; Ghilardi V; Livraghi L; Milesi L; Rota Caremoli E; Tondini C
    Future Oncol; 2014 Feb; 10(2):233-9. PubMed ID: 24490609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice.
    Fabi A; Moscetti L; Ciccarese M; Caramanti M; Salesi N; La Verde N; Russillo M; Generali D; Scandurra G; Vari S; Pacetti U; Cognetti F; Giannarelli D
    Future Oncol; 2015; 11(3):431-8. PubMed ID: 25675124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer.
    O'Shaughnessy J; Kaklamani V; Kalinsky K
    Future Oncol; 2019 May; 15(14):1641-1653. PubMed ID: 30892083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.